Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more
Alaunos Therapeutics Inc (TCRT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.301x
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has a cash flow conversion efficiency ratio of -0.301x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-844.00K) by net assets ($2.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alaunos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Alaunos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alaunos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alaunos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cemat A/S
CO:CEMAT
|
0.066x |
|
Sundaram Multi Pap Limited
NSE:SUNDARAM
|
-44.737x |
|
PT Superior Prima Sukses Tbk
JK:BLES
|
0.058x |
|
Sarytogan Graphite Ltd
AU:SGA
|
-0.038x |
|
Sienna Resources Inc
PINK:SNNAF
|
-0.055x |
|
Bulletin Resources Limited
F:7BR
|
-0.045x |
|
PT Agung Menjangan Mas Tbk
JK:AMMS
|
-0.023x |
|
Mountain Province Diamonds Inc
PINK:MPVDF
|
0.020x |
Annual Cash Flow Conversion Efficiency for Alaunos Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Alaunos Therapeutics Inc from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.06 Million | $-4.97 Million | -2.410x | +49.58% |
| 2023-12-31 | $6.31 Million | $-30.14 Million | -4.779x | -530.33% |
| 2022-12-31 | $38.55 Million | $-29.23 Million | -0.758x | +28.39% |
| 2021-12-31 | $58.06 Million | $-61.47 Million | -1.059x | -130.24% |
| 2020-12-31 | $123.98 Million | $-57.01 Million | -0.460x | -6.94% |
| 2019-12-31 | $95.01 Million | $-40.85 Million | -0.430x | +25.61% |
| 2018-12-31 | $85.56 Million | $-49.46 Million | -0.578x | -202.35% |
| 2017-12-31 | $-96.81 Million | $-54.67 Million | 0.565x | -25.16% |
| 2016-12-31 | $-77.30 Million | $-58.33 Million | 0.755x | +659355.55% |
| 2015-12-31 | $87.37 Million | $-10.00K | 0.000x | +99.99% |
| 2014-12-31 | $33.84 Million | $-36.65 Million | -1.083x | +10.13% |
| 2013-12-31 | $49.38 Million | $-59.51 Million | -1.205x | +25.95% |
| 2012-12-31 | $48.45 Million | $-78.83 Million | -1.627x | -200.04% |
| 2011-12-31 | $71.61 Million | $-38.84 Million | -0.542x | +15.86% |
| 2010-12-31 | $30.55 Million | $-19.69 Million | -0.645x | -47.35% |
| 2009-12-31 | $28.10 Million | $-12.29 Million | -0.437x | +87.47% |
| 2008-12-31 | $6.74 Million | $-23.52 Million | -3.490x | -389.56% |
| 2007-12-31 | $30.37 Million | $-21.65 Million | -0.713x | -31.16% |
| 2006-12-31 | $26.53 Million | $-14.42 Million | -0.544x | +55.42% |
| 2005-12-31 | $7.20 Million | $-8.78 Million | -1.219x | -450.55% |
| 2004-12-31 | $-21.02K | $-7.31K | 0.348x | -4.28% |
| 2003-12-31 | $-25.69K | $-9.33K | 0.363x | -46.49% |
| 2002-12-31 | $-17.33K | $-11.77K | 0.679x | -94.13% |
| 2001-12-31 | $-2.62K | $-30.26K | 11.570x | -- |